NCT00687505 2021-12-13
Safety Study of FP-1039 To Treat Cancer
Five Prime Therapeutics, Inc.
Phase 1 Completed
Clinical Trials
3 trialsNCT01244438 2021-12-13
Study of FP-1039 in Subjects With Endometrial Cancers
Five Prime Therapeutics, Inc.
Phase 2 Withdrawn
NCT01868022 2019-08-19
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
GlaxoSmithKline
Phase 1 Completed